Corosolic acid (CRA) is found in various plants and has been used as a health food supplement worldwide. Although it has been reported that CRA exhibits significant anticancer activity, the effect of this compound on prostate cancer remains unknown.
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Corosolic acid (CRA) is found in various plants and has been used as a health food supplement worldwide. Although it has been reported that CRA exhibits significant anticancer activity, the effect of this compound on prostate cancer remains unknown.
In this study, we investigated the effect of CRA on cellular transformation and the reactivation of nuclear factor erythroid 2-related factor 2 (Nrf2) through epigenetic regulation in TRAMP-C1 prostate cells. Specifically, we found that CRA inhibited anchorage-independent growth of prostate cancer TRAMP-C1 cells but not Nrf2 knockout prostate cancer TRAMP-C1 cells. Moreover, CRA induced mRNA and protein expression of Nrf2, heme oxygenase-1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1 (NQO1). Bisulfite genomic sequencing and methylated DNA immunoprecipitation results revealed that CRA treatment decreased the level of methylation of the first five CpG sites of the Nrf2 promoter. Histone modification was analyzed using a chromatin immunoprecipitation (ChIP) assay, which revealed that CRA treatment increased the acetylation of histone H3 lysine 27 (H3K27ac) while decreasing the trimethylation of histone H3 lysine 27 (H3K27me3) in the promoter region of Nrf2. Furthermore, CRA treatment attenuated the protein expression of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). These findings indicate that CRA has a significant anticancer effect in TRAMP-C1 cells, which could be partly attributed to epigenetics including its ability to epigenetically restore the expression of Nrf2.
contribute to PCa development. 2, 3 The major epigenetic processes that regulate gene expression are DNA methylation, alterations in the chromatin structure due to the post-translational modification of histones and certain non-histone proteins, and microRNAs. Epigenetics has attracted much attention because epigenetic interventions may reverse aberrant epigenetic modifications, and epigenetic therapy has been hypothesized to be a viable strategy for treating cancer.
Many studies have attempted to develop inhibitors of epigenetic mediators, such as DNA methyltransferase (DNMT), histone deacetylase (HDAC), enhancer of zeste homolog 2, DOT1-like histone H3K79 methyltransferase, and bromodomain and extraterminal domain proteins.
Oxidative stress is the overproduction or imbalanced production of reactive oxygen species (ROS), which significantly influence cancer cell survival, proliferation, invasion, angiogenesis, apoptosis, and chemo-and radio-therapy resistance. 4 To prevent the DNA damage and mutagenic events caused by oxidative stress, cells have evolved an elaborate and powerful cellular defense machinery against ROS, and the transcription factor nuclear factor erythroid 2-related factor 2 was used to assess cell viability.
| Colony formation assay
The colony formation assay was performed as previously described. 22 Briefly, sh-Mock and sh-Nrf2 cells were treated with 0.1% DMSO, either 2, 4, or 8 µM CRA for 5 days. On day 5, the pretreated cells were transferred to 1 mL of BME containing 0.33% agar, which was layered over 3 mL of BME containing 0.5% agar and 10% FBS in 6-well plates.
The cells were maintained in soft agar at 37°C in a humidified atmosphere with 5% CO 2 for an additional 14 days. Colonies were photographed using a computerized microscope system with the Nikon ACT-1 program (Version 2.20) and counted using ImageJ software (Version 1.48d; NIH).
| RNA extraction and quantitative real-time PCR
Total RNA was extracted from cells using the GeneJET RNA Purification Kit (ThermoFisher Scientific, Waltham, MA), and cDNA was synthesized from the total RNA using the SuperScript III First-Strand Synthesis System (Invitrogen, Grand Island, NY)
according to the manufacturer's instructions. To assess the RNA expression of specific genes, the cDNA was used as the template for real-time PCR using Power SYBR Green PCR Master Mix 
| Methylated DNA immunoprecipitation (MeDIP) analysis
To confirm the results of the BGS, MeDIP was performed using the Methylamp Methylated DNA Capture (MeDIP) Kit (Epigentek, Farmingdale, NY), as described in our previous work. 14 Briefly, DNA extracted from treated cells was sonicated using a Bioruptor sonicator (Diagenode Inc., Sparta, NJ) to shear the DNA into lengths of 200-1000 bp. The sonicated DNA was incubated at 95°C for 2 min, followed by immunoprecipitation with an anti-5-methylcytosine antibody at room temperature for 2 h. After washing and purification, the methylation status was quantified via a qPCR assay using the primer set 5′-GAGGTCACCACAACAC-GAAC-3′ (forward) and 5′-ATCTCATAAGGCCCCACCTC-3′ (reverse) to cover the DNA sequence of the first five CpGs of murine Nrf2. The enrichment of methylated DNA in each treatment was calculated according to the standard curve of the serial diluted input DNA. The relative ratios of methylated DNA were then calculated based on the control, which was defined as 100% DNA methylation.
| Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the MAGnify™ Chromatin
Immunoprecipitation system according to manufacturer's protocol 
| Western blot analysis
After washing with PBS, treated cells were harvested with trypsin and lysed using radio-immunoprecipitation assay buffer (Cell Signaling Technology) containing a protein inhibitor cocktail. The concentrations of the protein extracts were measured using a bicinchoninic acid assay (Pierce, Rockford, IL). Equal amounts of protein were resolved using SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad), and then blocked at room temperature for 2 h. For immunoblotting, the membranes were incubated with the respective primary antibodies at 4°C overnight, followed by a 2-h incubation with the secondary antibody at room temperature. The bands were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific) and were analyzed using ImageJ version 1.48d.
| HDAC and DNMT activity
DNMT activity and HDAC activity assays were conducted using a DNMT activity/ inhibition assay kit and an HDAC activity/ inhibition assay kit (Epigentek). The nuclear protein was isolated using the NEPER Nuclear and Cytoplasmic Protein Extraction Kit (Thermo Scientific, Pittsburgh, PA). The relative DNMT and HDAC activities were calculated based on the ratio of the CRA treatment group to the control group after normalization to the protein amount.
| Statistical analysis
All analyses were performed using SPSS software, version SPSS19.0 (Chicago, IL). The data are presented as mean ± standard error (SEM).
The statistical analyses were conducted using a one-way analysis of variance (ANOVA) or Student's t-test. P values less than 0.05 were considered statistically significant. ( Figures 2B and 2C ). These results suggest that Nrf2 played an important role in the CRA-mediated suppression of anchorageindependent growth of TRAMP-C1 cells.
| CRA increased the mRNA and protein expression levels of Nrf2 and its downstream genes
Nrf2 plays a crucial role during oxidative stress in cells. Previous studies have proven that the expression levels of Nrf2 and its downstream genes are decreased in TRAMP prostate cancer. 8, 9 In this study, qPCR assays were applied to investigate the effect of CRA on 
| CRA decreased CpG methylation in the promoter region of Nrf2
Our previous report identified the first five CpG sites in the promoter of Nrf2 as being hypermethylated in the TRAMP-C1 cell line. 14, 15, 23 In this study, we examined whether CRA could reverse the methylation in the promoter region of Nrf2 using BGS and MeDIP assays. As shown in Figures 5A and 5B, the BGS results revealed a hypermethylated region in the promoter of Nrf2 in TRAMP-C1 cells, and 90% of the CpG sites were methylated. Notably, after treatment with 4 µM CRA or AZA plus TSA (positive control) for 5 days, the percentage of methylated CpG sites significantly decreased to 75% or 70%, respectively (P < 0.05, one-way ANOVA). However, there was no significant change in the methylation of CpG sites when the cells were treated with 2 µM CRA.
These results indicate that CRA can reverse the CpG methylation status of the Nrf2 promoter, which may contribute to the ability of this drug to increase Nrf2 expression.
To verify the BGS results, an MeDIP assay was performed, which uses an anti-5-methylcytosine antibody to capture methylated genomic DNA without bisulfite conversion. The enriched methylated fractions were then measured using a qPCR assay. As shown in Figure 5C , the ratio of methylated DNA relative to the control was significantly reduced in the 4 µM CRA or the combination of 5-AZA/TSA treatment groups (P < 0.05, one-way ANOVA). Taken together, these data indicate that 4 µM CRA can decrease CpG methylation in the promoter region of Nrf2 in TRAMP-C1 cells.
CRA increased the acetylation of histone H3 lysine 27 (H3K27ac) and decreased the trimethylation of histone H3 lysine 27 (H3K27Me3) in the promoter region of Nrf2
In addition to DNA methylation, histone modification is also a critical process in the regulation of gene expression. In this study, a
ChIP analysis was performed to investigate the enrichment of Compared to the control, H3K27ac enrichment was increased after treatment with 4 µM CRA ( Figure 5D ), while the association of H3K27Me3 with the promoter of Nrf2 was decreased, as shown in Figure 5E (P < 0.05, Student's t-test).
| CRA downregulated the expressions and activities of epigenetically modifying enzymes in TRAMP-C1 cells
To explore the potential epigenetic mechanism by which CRA decreases Nrf2 promoter methylation and increases the Nrf2 level,
we examined the effect of CRA on the expression of epigenetically modifying enzymes. DNA methylation is catalyzed by enzymes known as DNMTs, including DNMT1, DNMT3a, and DNMT3b. As shown in Figure 6A , CRA treatment decreased the protein levels of DNMT1, DNMT3a, and DNMT3b in a dose-dependent manner in TRAMP-C1 cells (P < 0.05, one-way ANOVA). 
| DISCUSSION
PCa is one of the most common non-cutaneous malignancies among men worldwide. 1 The development and formation of a prostate carcinoma from a preneoplastic lesion to androgen-independent invasive carcinoma usually occurs over several decades, 2 allowing the possibility of using chemopreventive agents to delay this process and reduce the morbidity of PCa. Many natural phytochemicals, such as curcumin, 15 sulforaphane, 14 and Z-ligustilide, 13 have been shown to have cancer chemopreventive activity regarding PCa. CRA, a triterpenoid, has been identified in many Chinese medicinal herbs and has been used as an anti-diabetes agent in many food supplementary products. 24 In addition to the excellent anti-diabetic activity of this compound, cytotoxic activity against several human cancer cell lines has also been reported for CRA. 25 Specifically, CRA induced mitochondria-mediated and caspase-dependent apoptosis in A549 cells 26 and also showed anticancer activity against colon cancer cells by promoting the degradation of β-catenin. 27 In our study, CRA significantly inhibited the proliferation of TRAMP-C1 cells. Moreover, this compound also significantly inhibited sh-mock TRAMP-C1 cell colony formation, demonstrating the ability of CRA to prevent prostate carcinogenesis in vitro.
Oxidative stress, which results from a perturbation in the production and removal of ROS, may damage DNA and proteins, thereby disturbing cellular processes. 28 To respond to oxidative stress, FIGURE 3 CRA increased the mRNA expression levels of Nrf2 and Nrf2 target genes in TRAMP-C1 cells. TRAMP-C1 cells were treated with CRA (2, 4, and 8 µM) for 5 days. After treatment, mRNA was isolated from the TRAMP-C1 cells, and the expression levels of target genes were determined using real-time qPCR assays with β-actin as an internal control. The graphical data are expressed as the mean ± SEM from three independent experiments. *P < 0.05 compared to the control organisms create a highly reducing intracellular environment by regulating phase II antioxidant and detoxification enzymes, such as HO-1 (antioxidant), NQO1, and UGT1A1 (detoxification). 29 It is widely accepted that the transcription of these enzymes is regulated by the ARE. 29, 30 Nrf2 is a transcription factor that binds to the ARE and mediates ARE-dependent gene activation. Therefore, Nrf2 plays a crucial role in the oxidative stress response and its related diseases. 3, 4, 30, 31, 32 The expression of Nrf2 is decreased in human prostate cancer 33 and in TRAMP mice. 10 Many natural compounds, such as Z-ligustilide, 13 sulforaphane, 14 and curcumin, 15 Figure 5A ). This hypomethylation was confirmed by the MeDIP assay, which showed that the ratio of methylated DNA of the first five CpGs in the Nrf2 promoter was lower in the TRAMP-C1 cells treated with CRA (4 µM) than in the control cells. These results suggest that CRA may modulate DNA methylation, which is implicated in carcinogenesis.
Furthermore, DNA methylation is a covalent chemical modification that is catalyzed by DNMT. 35 We found that CRA decreased the protein levels of DNMT1, DNMT3a, and DNMT3b, which may be an underlying mechanism for the CRA-induced demethylation of Nrf2.
In addition to DNA methylation, histone modifications have also been implicated in prostate carcinogenesis. 36, 37 The N-terminal tails of histones can undergo a variety of post-translational covalent modifications, including acetylation, methylation, phosphorylation, ubiquitination, and glycosylation. 38 In general, histone acetylation, which is regulated by HDACs, correlates with transcriptional activation. In PCa, HDACs 1, 2, and 3 are strongly expressed and may correlate with increased proliferative capacity. 38 Therefore, the discovery of selective HDAC inhibitors has had significant implications for cancer therapy. 36, 37 Notably, in our study, CRA significantly decreased the protein levels of HDAC1, HDAC3, HDAC4, HDAC5, and HDAC6 in TRAMP-C1 cells. Moreover, CRA increased the enrichment of H3K27AC at the promoter of Nrf2. In contrast to histone acetylation, histone methylation on arginine, and lysine may be associated with either gene activation or repression. 36, 37, 39 Many studies have characterized H3K27me3 as an epigenetic feature of histone methylation-related prostate cancer progression. 40, 41 In our study, CRA decreased the enrichment of H3K27Me3 at the promoter of Nrf2. Taken together, these results imply that CRA prevents DNA hypermethylation by regulating DNMTs and HDACs, unlike 5-AZA and TSA, which specifically inhibit only DNA methylation and histone deacetylation.
Prostate carcinogenesis is a complicated process regulated by an interlinked network of many genes. Aberrant alterations of the methylation patterns are common features of PCa development and progression. 35 More than 100 genes such as GSTP1, RARB2, RASSF1A, APC, COX2, MDR1, TIG1, HIC1 have been shown to be inactivated by promoter hypermethylation in PCa. 35 In our study, there was a significant decrease in the protein levels of DMNTs and HDACs FIGURE 4 CRA increased the expression levels of Nrf2, HO-1, and NQO1 in TRAMP-C1 cells. TRAMP-C1 cells were treated with CRA (2, 4, and 8 µM) for 5 days. After treatment, the cells were lysed, and the expression levels of proteins were determined by western blot analysis. The relative protein levels in the treatment groups were quantified and compared to that of the control group. β-actin was used as an internal control to normalize loading. The data are presented as the mean ± SEM from three independent experiments. *P < 0.05, **P < 0.01 compared to the control group after CRA treatment, suggesting the possibility that CRA might also change the methylation patterns of other genes besides Nrf2.
However, further studies are needed to investigate the effects of CRA on the methylation of other genes. 
